Background and aim: Currently, different regimens are used for Helicobacter pylori eradication. The aim of this study is to compare the efficacy and safety of sequential and standard triple therapy for Helicobacter pylori eradication in Bandar Abbas in 2018.
Methods: This randomized controlled trial was done on 150 patients in Bandar Abbas in 2018. Patients were randomly assigned into two groups either to receive standard triple therapy or sequential therapy for Helicobacter pylori eradication. Patients were followed for helicobacter eradication, minor and major side effects and drug intolerance. Data were analyzed using SPSS 23.0 software.
Results: Two groups were similar in baseline characteristics. Helicobacter pylori eradication was reported in 70 (90.9 %) in the sequential and 54 (74 %) in the standard triple therapy group (p=0.006). Minor side effects were reported in 20 (26 %) in the sequential and 36 (49.3 %) in the standard triple therapy (p=0.003). Major side effects (p=0.142) and drug intolerance (p=0.480) were similar in both groups.
Conclusion: Sequential therapy is more effective and has lower rate of minor complications in eradication of Helicobacter pylori. 
Trial registration: The protocol of study was registered at the Iranian Registry of Clinical Trials (IRCT) with ID number of IRCT20180131038581N2.
Funding: Hormozgan University of Medical Sciences, thesis number: 93-95/231
Keywords: Helicobacter pylori, Sequential therapy, Triple therapy


» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/7378
Adidas Adilette SlidesAir Force 1 Sage Low

The  most recent editorial (June 2021)

Ethics of Publishing Case Reports: Do We Need Ethics Approval and Patient Consent?

An editorial by Dr. Mehrdad Jalalian

Read more.

The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.


To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here


Our previous editorial (June 2020)

Lessons from COVID-19 pandemic and the Morocco’s success story.

An editorial by Dr. Benksim Abdelhafid (Morocco)

Read more.


The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:


TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:

Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: